Limited Effectiveness of Smoking Cessation Programs in South Korea

Regulations by 2FIRSTS.ai
Oct.09.2023
Limited Effectiveness of Smoking Cessation Programs in South Korea
Korean smokers' completion rate of smoking cessation programs funded by a 263.1 billion KRW budget remains below 30%.

According to a report from South Korean media outlet Sportschosun on October 8th, data from the South Korean National Assembly's Health and Welfare Committee reveals that over the past five years, approximately 263.1 billion Korean won (approximately 1.423 billion Chinese yuan) have been allocated in the budget to support smoking cessation programs. However, the completion rate among participants is less than 30%, indicating limited effectiveness.

 

A total of 263.1 billion South Korean won has been invested.

 

South Korean lawmaker Bak Jong-heon, a member of the National Assembly's Health and Welfare Committee, has shared his analysis of data on "smoking cessation programs and current smoking rates over the past five years." The data reveals that while smoking rates are decreasing, the overall cost of healthcare coverage due to smoking-related illnesses is on the rise.

 

The smoking cessation support program in South Korea has a duration of 8 to 12 weeks, during which participants receive up to six consultations with doctors and partial coverage of the cost for purchasing smoking cessation medications, including adjunct medications. According to the budget overview of the smoking cessation support program in the past five years, a total of 263.1 billion Korean won has been allocated thus far.

 

However, according to the current participation status in smoking cessation programs over the past five years, the number of participants has decreased from 280,000 in 2019 to 150,000 in 2022, marking a 46.5% decline. In terms of completion rate, only 35.94% of participants managed to complete the entire course in 2022, meaning that out of every ten individuals, only three were able to finish it. The effectiveness of the program appears to be minuscule compared to the resources invested.

 

According to the data, more than half of the participants opted for a drug regimen lasting 56 to 84 days. Smoking-related medical insurance expenses have cost a total of 16.4 trillion Korean won (approximately 88.7 billion Chinese yuan) in the past five years. In 2022, the expenses reached 3.6 trillion Korean won, which is a 24.6% increase compared to the 2.9 trillion Korean won in 2018.

 

The usage rate of e-cigarettes has increased to 3.2%.

 

According to the past five-year data on smoking rates among individuals aged 19 and above, the smoking rate has decreased from 22.3% in 2017 to 19.3% in 2021. Age-group breakdown data reveals that, except for the 60-69 age group, which witnessed a slight increase from 14.4% in 2017 to 15.1% in 2021, the smoking rates in all other age groups have been declining.

 

Gender data shows that the smoking rate among men has decreased from 38.1% in 2017 to 31.3% in 2021, while the smoking rate among women has increased from 6% in 2017 to 6.9% in 2021. In comparison, the usage rate of e-cigarettes has increased from 2.7% in 2017 to 3.2% in 2021, while the usage rate of traditional cigarettes has declined from 6.2% in 2019 to 4.6% in 2021.

 

Furthermore, according to lung cancer data from the past five years, the number of cases has increased from 91,192 in 2018 to 116,477 in 2022, representing a growth rate of 28%. Detailed data reveals that in 2022, individuals aged 70 and above account for 34% of the total, those aged 60 make up 32%, and those aged 50 constitute 12%. From 2021 to 2022, there has been a 3% increase in cases among individuals in their twenties and a 6% increase among those in their thirties.

 

Bai Zhongxun emphasized, "The total healthcare costs and donations for national health promotion caused by smoking are increasing, so we should actively seek strategies to effectively implement smoking cessation programs and improve completion rates."

 

Disclaimer: 
This article is translated from an original Chinese article available on 2firsts.cn by AI, and has been reviewed and edited by 2FIRSTS's English editorial team. The Chinese original text is the only authoritative source of information. The exclusive copyright and license rights to this article are held by 2FIRSTS Technology Co., Ltd. Any reproduction, reprinting, or redistribution of this article, either in part or in full, requires express written permission from 2FIRSTS and must include clear attribution along with a link to this content. Non-compliance may result in legal action. 2FIRSTS Technology Co., Ltd. reserves the right to pursue legal actions in case of unauthorized use or distribution.